Xbrane Biopharma AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
02/05 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
22/04 | Transcript : Xbrane Biopharma AB - Special Call |
Sales 2024 * | 344M 31.75M 2.65B | Sales 2025 * | 680M 62.87M 5.25B | Capitalization | 311M 28.76M 2.4B |
---|---|---|---|---|---|
Net income 2024 * | -186M -17.19M -1.43B | Net income 2025 * | 104M 9.61M 802M | EV / Sales 2024 * | 0.82 x |
Net cash position 2024 * | 28.17M 2.6M 217M | Net Debt 2025 * | 116M 10.7M 893M | EV / Sales 2025 * | 0.63 x |
P/E ratio 2024 * |
-1.51
x | P/E ratio 2025 * |
4.25
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.26% |
Latest transcript on Xbrane Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 01/15/01 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 11/21/11 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 09/17/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 01/15/01 | |
Director/Board Member | 70 | 01/15/01 | |
Director/Board Member | 53 | 01/20/01 |
1st Jan change | Capi. | |
---|---|---|
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |